HHS & Healthcare Contracts Intelligence — July 09, 2026

The cost-sharing pricing type means Spero Therapeutics shares financial risk with HHS, reducing profit potential compared to fixed-price contracts. With $35.5M already outlaid and an 8-year performance period, margin compression is a concern.

The cost-plus-fixed-fee pricing limits margin upside for Technical Resources International, even if all options through 2032 are exercised. Full-and-open competition with no set-aside suggests no preferential advantage.

Both awards are cost-no-fee, meaning nonprofits recover costs only. Combined $51.7M in NIH funding provides stable revenue but zero margin, with 80%+ subawarded to other entities, diluting direct financial impact.

All four contracts were awarded under full and open competition with no set-asides, meaning no incumbent advantage or competitive moat. Spero Therapeutics, Technical Resources International, Seattle Children's Hospital, and Northwestern University all face re-compete risk without preferential status.

Two of four awards ($51.7M) are concentrated in NIH/NIAID infectious disease structural biology research, with both Seattle Children's Hospital and Northwestern University receiving similar cost-no-fee contracts on the same date (2022-08-15). This creates agency-specific budget risk if NIH funding shifts.

Spero Therapeutics' $49.2M cost-sharing contract carries medium execution risk due to shared financial burden and 8-year duration. As a small disadvantaged business, Spero may face resource constraints in delivering biotechnology R&D outcomes.

Technical Resources International has a potential $111.9M total contract value through 2032 if all options are exercised, implying ~$11.2M annual revenue. Option exercises would signal deepening NIH relationship and stable growth.

Spero Therapeutics' $49.2M BARDA contract aligns with pandemic preparedness priorities, which may see increased funding under future health security legislation. Contract modifications or extensions beyond 2026 could expand total value.

Two contracts totaling $51.7M to Seattle Children's Hospital and Northwestern University for structural biology research on infectious diseases, both awarded on the same date (2022-08-15), demonstrate sustained NIH/NIAID investment in basic research despite budget uncertainty.

All four awards were full-and-open competition with no set-asides or sole-source designations, indicating that incumbents Spero Therapeutics, Technical Resources International, Seattle Children's Hospital, and Northwestern University have no preferential status for follow-on work.

{"entity"=>"Spero Therapeutics, Inc.", "reason"=>"Only for-profit awardee in this digest with $49.2M BARDA contract; revenue recognition and margin performance are key to investment thesis.", "trigger"=>"Quarterly financial reports showing revenue from BARDA contract; contract modification or extension announcement beyond 2026"}

{"entity"=>"Technical Resources International, Inc.", "reason"=>"Potential $111.9M total contract value if all options exercised; option exercise dates signal growth trajectory.", "trigger"=>"Option exercise announcements for years 3-10 of NIH/NCI contract"}

{"entity"=>"NIH/NIAID", "reason"=>"Two contracts ($51.7M) concentrated in infectious disease research; budget changes directly impact Seattle Children's Hospital and Northwestern University.", "trigger"=>"FY2024-2025 NIH budget appropriations; NIAID funding announcements"}